Editorial  May 9, 2023 The Future of Clinical Trials in Idiopathic Pulmonary Fibrosis Anna J. Podolanczuk, Luca Richeldi, Fernando J. Martinez JAMA. 2023;329(18):1554-1555. doi:10.1001/jama.2022.23955 Idiopathic pulmonary fibrosis (IPF) currently affects about 100 000 individuals in the US, and millions globally. Patients living with IPF experience disabling symptoms and progressive loss of lung function.1 The 2 treatments approved by th...

ORIGINAL ARTICLE Randomized Trial of Early Detection and Treatment of Postpartum Hemorrhage Ioannis Gallos, Adam Devall, James Martin, et al N Engl J Med May 9, 2023DOI: 10.1056/NEJMoa2303966 Abstract BACKGROUND Delays in the detection or treatment of postpartum hemorrhage can result in complications or death. A blood-collection drape can help provide objective, accurate, and early diagnosis of postpartum hemorrhage, and delayed or inconsistent use of ef...

Editorial  May 25, 2023 Disentangling the Postacute Sequelae of SARS-CoV-2: E Unibus Pluram (From One, Many) Robert Gross, Vincent Lo Re III JAMA. Published online May 25, 2023. doi:10.1001/jama.2023.8961 Early in the COVID-19 pandemic, patients and clinicians reported the persistence of initial symptoms and the onset of new symptoms after the acute phase of SARS-CoV-2 infection, collectively referred to as postacute sequelae of SARS-CoV...

ORIGINAL ARTICLE A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis Jay Tuttle, Edit Drescher, Jesus Abraham Simón-Campos, et al N Engl J Med 2023; 388:1853-1862DOI: 10.1056/NEJMoa2209856 Abstract BACKGROUND Peresolimab is a humanized IgG1 monoclonal antibody designed to stimulate the endogenous programmed cell death protein 1 (PD-1) inhibitory pathway. Stimulation of this pathway would be a novel approach to the treatment of patients wi...

Editorial  April 20, 2023 Informing a Rational Approach to Antimicrobial Prophylaxis in Open Pancreatoduodenectomy Anthony Charles, Preeti N. Malani JAMA. 2023;329(18):1556-1557. doi:10.1001/jama.2023.6275 Despite numerous advances in perioperative care, surgical site infection (SSI) remains a frequent complication after major abdominal surgery, with gastrointestinal procedures among the highest risk for infection.1Besides the increased length of stay ...

ICU Management & Practice, Volume 23 - Issue 1, 2023 Tachycardia in Sepsis: Friend or Foe? An overview of tachycardia in sepsis, the importance of rate control and the beneficial effects of beta-blockers. Sepsis and Tachycardia – Aetiologic Factors During sepsis, the sympathetic nervous system plays a key role in maintaining cardiac output and blood pressure. This is achieved through changes in heart rate, contractility, and vascular tone. The proper ...

ORIGINAL ARTICLE Transcatheter Repair for Patients with Tricuspid Regurgitation Paul Sorajja, Brian Whisenant, Nadira Hamid, et al N Engl J Med 2023; 388:1833-1842DOI: 10.1056/NEJMoa2300525 Abstract BACKGROUND Severe tricuspid regurgitation is a debilitating condition that is associated with substantial morbidity and often with poor quality of life. Decreasing tricuspid regurgitation may reduce symptoms and improve clinical outcomes in patients with this...

Editorial  May 9, 2023 The Role of Prophylactic Antibiotics for Patients With Severe Alcohol-Related Hepatitis Ewan Forrest, William Bernal JAMA. 2023;329(18):1552-1553. doi:10.1001/jama.2023.1729 Few effective pharmacologic therapies are available for alcohol-related hepatitis. In patients diagnosed with alcohol-related hepatitis, greater severity of liver injury and systemic inflammation are associated independently with early mortality.1&n...

Original Investigation  May 25, 2023 Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection Tanayott Thaweethai, Sarah E. Jolley, Elizabeth W. Karlson, et al JAMA. Published online May 25, 2023. doi:10.1001/jama.2023.8823 Key Points Question  What symptoms are differentially present in SARS-CoV-2–infected individuals 6 months or more after infection compared with uninfected individuals, and what symptom-based c...

Original Investigation  April 20, 2023 Piperacillin-Tazobactam Compared With Cefoxitin as Antimicrobial Prophylaxis for Pancreatoduodenectomy: A Randomized Clinical Trial Michael I. D’Angelica, Ryan J. Ellis, Jason B. Liu, et al JAMA. 2023;329(18):1579-1588. doi:10.1001/jama.2023.5728 Key Points Question  Does use of perioperative broad-spectrum antibiotics reduce postoperative surgical site infection after open pancreatoduodenec...